Karyopharm Therapeutics Q2 2024 GAAP EPS $(0.20) Beats $(0.30) Estimate, Sales $42.786M Beat $36.179M Estimate
Portfolio Pulse from Benzinga Newsdesk
Karyopharm Therapeutics (NASDAQ:KPTI) reported better-than-expected Q2 2024 results with a GAAP EPS of $(0.20), beating the estimate of $(0.30). Sales also surpassed expectations, reaching $42.786 million against the $36.179 million estimate.
August 06, 2024 | 11:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Karyopharm Therapeutics reported a GAAP EPS of $(0.20) for Q2 2024, beating the analyst estimate of $(0.30). Sales also exceeded expectations, coming in at $42.786 million compared to the $36.179 million estimate.
The better-than-expected earnings and sales figures are likely to positively impact KPTI's stock price in the short term. Beating both EPS and sales estimates by significant margins indicates strong performance and could boost investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100